Can we predict discordant RECIST 1.1 evaluations in double read clinical trials?

Front Oncol · 2023 · PMC10585359 · PMID 37869080

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

weakly significantno p-value reported

In lung cancer trials, although risk factors for inter-reader discrepancies are known, they are weakly significant, the ability to predict discrepancies from baseline data is limited.

also in 491 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.